You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
The ATTEST Clinical Study1
was the first randomized controlled study to introduce progression from paroxysmal to persistent AF as a clinical endpoint in an AF study. ATTEST demonstrated that early RF catheter ablation—as part of standard-of-care AF management including antiarrhythmic drugs—is superior to guideline-directed antiarrhythmic drug therapy alone in delaying AF progression.
The study included 29 centers across 13 countries.
255 patients ≥60 years old with paroxysmal AF ≥2 years participated in the study.
Superiority of RF Ablation Over Antiarrhythmic Drug Therapy Alone to Delay AF Progression
The superiority of RF ablation over antiarrhythmic drug therapy alone in delaying disease progression was observed at 1-year follow-up and strengthened by the 3-year follow-up.
Antiarrhythmic Drug Therapy and Older Age Were Associated With AF Progression
Treatment modality and age were associated with AF progression, suggesting that early RF ablation can delay disease progression.
Download the Summary
View the Graphic Abstract
Read the Article
Patient Inclusion and Exclusion Criteria
Key Inclusion Criteria
- ≥60 years old with paroxysmal AF ≥2 years
- ≥2 episodes over the 6 months preceding enrollment
- Failed treatment with 1–2 antiarrhythmic drugs
- HATCH score 1–4
Key Exclusion Criteria
- Reversible AF
- Previous diagnosis of persistent/permanent AF/AT
- Cardioversion >48 h after onset of AF/AT
- Recent cardiovascular events
Study Design and Patient Follow-Up
Abbreviations, Footnotes, and References
AAD, antiarrhythmic drug; AF, atrial fibrillation; AT, atrial tachycardia; ECG, electrocardiogram; FU, follow-up; HATCH score: hypertension = 1, age >75 = 1, transient ischemic attack or stroke = 2, chronic obstructive pulmonary disease = 1, heart failure = 2; ITT, intention to treat; PP, per protocol; RF, radiofrequency; TTM, transtelephonic monitoring.
a RF ablation was performed with noncontact force- and contact force-sensing catheters (NAVISTAR® THERMOCOOL ® Catheter, THERMOCOOL® SF NAV Catheter Bi-Directional Navigation Catheter, THERMOCOOL SMARTTOUCH ® Bi-Directional Navigation Catheter, THERMOCOOL SMARTTOUCH ® Uni-Directional Navigation Catheter, NAVISTAR RMT THERMOCOOL ® Catheter) in conjunction with a 3-dimensional electroanatomic mapping system (CARTO® 3, CARTO® XP, or CARTO® RMT).
b Transtelephonic monitoring transmission per specified schedule or whenever patients experienced symptoms. Once AF/AT was identified, daily TTM was initiated for 7 consecutive days.
1. Kuck K-H, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: The randomized controlled Atrial Fibrillation Progression Trial (ATTEST). Europace. 2021;23(3):362-369.
THERMOCOOL® Navigation Catheters are indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with CARTO® 3 Systems (excluding NAVISTAR™ RMT THERMOCOOL™ Catheter).
Important information: Prior to use, refer to the instructions for use supplied with the device for indications, contraindications, side effects, warnings and precautions.
Caution: US law restricts this device to sale by or on the order of a physician.